

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: **RESINCO CAPITAL PARTNERS INC. ("Resinco" or the "Issuer")**.

Trading Symbol: **RIN**

Number of Outstanding Listed Securities: **122,186,007 Common shares were issued and outstanding as of January 31, 2019**

Date: **February 1, 2019 (for the month of January 2019)**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

## Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Issuer is a global investment company which specializes in providing early stage financing to private and public companies as well as medical marijuana pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant position in early stage investment opportunities that adequately reflect the risk profile.**

2. Provide a general overview and discussion of the activities of management.

**During the month of January 2019, the Issuer entered into a definitive agreement with ReFormation Pharmaceuticals Corp. ("ReFormation") and acquired the remaining 51% of the issued and outstanding shares of ReFormation by way of a three-cornered amalgamation. ReFormation is a cannabis pharma company based in Toronto, Ontario and Oxford, United Kingdom. The Issuer previously acquired 49% of ReFormation's outstanding shares on October 23, 2018.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**There were no new products or services developed or offered during the month of January 2019.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**There were no products or services discontinued during the month of January 2019.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**There were no new business relationships entered into between the Issuer, the Issuer's affiliates or third parties during the month of January 2019.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**There were no contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced, expired or were terminated during the month of January 2019.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**During the month of January 2019, the Issuer entered into a definitive agreement with ReFormation and acquired the remaining 51% of the issued and outstanding shares of ReFormation by way of a three-cornered amalgamation, in consideration of the issuance of 29 million common shares of the Issuer to the shareholders of ReFormation. The acquisition of ReFormation is an arm's length transaction.**

8. Describe the acquisition of new customers or loss of customers.

**There were no acquisitions of new customers or loss of customers during the month of January 2019.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**There were no new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks during the month of January 2019.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**There were no employee hirings, terminations or lay-offs during the month of January 2019.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**There were no labour disputes during the month of January 2019.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**There were no legal proceedings to which the Issuer became a party to during the month of January 2019.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**There was no indebtedness incurred or repaid by the Issuer during the month of January 2019.**

14. Provide details of any securities issued and options or warrants granted.

**During the month of January 2019, the following securities were issued:**

Date of Issue	Security	Number Issued	Details of Issuance
Jan. 15, 2019	Common Shares	31,030,000	Acquisition
January 16, 2019	Common Shares	25,000	Exercise of Warrants

(1) These common shares were issued in connection with the acquisition of ReFormation with 29,000,000 common shares being issued to the shareholders of ReFormation and 2,030,000 common shares being issued to a finder in connection with the acquisition.

15. Provide details of any loans to or by Related Persons.

**There were no loans to or by Related Persons during the month of January 2019.**

16. Provide details of any changes in directors, officers or committee members.

**During the month of January 2019, there were no changes in directors, officers or committee members.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**Trends and risks that may impact the Issuer (in no specific order):**

**Interest rate risk**

The Issuer is exposed to interest rate risk to the extent that its cash balances bear variable rates of interest. The interest rate risks on cash and on the Issuer's obligations are not considered significant.

### Currency risk

The Issuer has foreign investments and is therefore subject to currency risk. Management believes these investment and transaction amounts are not significant and there are no material foreign currency commitments. The currency risk is therefore manageable and not significant. The Issuer does not currently use any derivative instruments to reduce its exposure to fluctuations in foreign currency exchange rates.

### Credit risk

Credit risk is the risk associated with the inability of a third party to fulfil its payment obligations. The Issuer is exposed to the risk that third parties that owe money or securities in connection with services provided, or for other purposes, will default on their underlying obligations.

Prior to accepting any service engagement or providing any loan, the Issuer assesses future recoverability by examining the entities' financial conditions, properties and assets, business development activities and management. The Issuer manages its exposure to credit risk by reviewing the outstanding balances on an ongoing basis, monitoring the amount attributable to each counterparty, and the length of time taken for amounts to be settled. Where necessary, management takes appropriate action to follow up on those balances considered overdue.

### Liquidity risk

Liquidity risk is the risk that the Issuer will have insufficient cash resources to meet its financial obligations as they become due. The Issuer's liquidity and operating results may be adversely affected if the Issuer does not have access to the capital markets, whether as a result of a downturn in general market conditions or related to matters specific to the Issuer, or if the value of the Issuer's investments decline, resulting in lower proceeds and/or losses on disposition. The Issuer generates cash flows primarily from the disposition of its investments and from its financing activities. The Issuer's investments focus on early-stage companies which can at times be relatively illiquid and if the Issuer decides to dispose of certain securities, it may not be able to do so at favorable prices at that time, or at all. However, the Issuer has sufficient marketable securities which are freely tradable and relatively liquid to fund its obligations as they become due under normal operating conditions such that, in the absence of overall market disruptions or exceptional circumstances, liquidity risk can be minimized.

### **Market risk**

**Market risk is the risk that the fair value of, or future cash flows from, the Issuer's financial instruments will significantly fluctuate due to changes in market prices. The value of the financial instruments can be affected by changes in interest rates, foreign exchange rates and equity and commodity prices. The Issuer is exposed to market risk in trading its investments and unfavourable market conditions could result in dispositions of investments at less than favourable prices. The Issuer's investments are primarily concentrated in early-stage companies, which results in exposure to higher volatility than broader market investments and indexes. The Issuer's investments are accounted for at fair value and are sensitive to changes in market bid prices, such that changes in market prices result in a proportionate change in the carrying value of the Issuer's investments.**

### **Concentration risk**

**The Issuer is subject to concentration risk due to the nature of the Issuer's operations as an investment company and the number of investments held in the portfolio which consists primarily of early-stage companies and their related technologies. As a result, the investment portfolio is directly exposed to the risks associated with companies operating in this industry sector.**

*[the balance of this page is left intentionally blank]*

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **February 1, 2019.**

**Alexander Somjen**  
 Name of Director or Senior  
 Officer

**"Alexander Somjen"**  
 Signature

**President & CEO**  
 Official Capacity

<b><i>Issuer Details</i></b> Name of Issuer	For Month End	Date of Report YY/MM/D
<b>Resinco Capital Partners Inc.</b>	<b>January 2019</b>	<b>2019/02/01</b>
Issuer Address		
<b>789 West Pender Street, Suite 810</b>		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
<b>Vancouver, B.C., V6C 1H2</b>	<b>(604) 687-3141</b>	<b>(604) 687-2038</b>
Contact Name	Contact Position	Contact Telephone No.
<b>Theo van der Linde</b>	<b>CFO</b>	<b>(778) 834-6272</b>
Contact Email Address	Web Site Address	
<b>theo@pashleth.com</b>	<b>N/A</b>	